Intellia Q3 net loss $113.2M; NTLA-2001 shows 93% TTR reduction, NTLA-2002 91% attack reduction

Intellia Therapeutics, Inc.

2022-Q3 EPS reported -$4.78 revenue$38,548,000

Net loss of $113.2M in Q3 2022 widened from $71.6M in Q3 2021; cash position $848.7M.
Collaboration revenue rose to $13.3M from $7.2M; R&D expenses increased to $96.7M.
NTLA-2001: mean serum TTR reductions of 93% (0.7 mg/kg) and 92% (1.0 mg/kg) at day 28.
NTLA-2002: 25 mg dose led to 91% mean reduction in HAE attacks through 16-week observation.
Expects to initiate NTLA-2002 Phase 2 in 1H 2023; plans IND filing for NTLA-3001 in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.